Astrazeneca (AZN) Accounts Payables (2009 - 2026)

Astrazeneca's Accounts Payables history runs 18 years deep, the most recent figure standing at -$22.5 billion for Q1 2026.

• In Q1 2026, Accounts Payables changed 0.17% year-over-year to -$22.5 billion; the TTM figure through Mar 2026 stood at -$22.5 billion (changed 0.17% YoY), while the FY2025 annual figure was -$25.3 billion, down 212.53% from the prior year.
• Accounts Payables was -$22.5 billion for Q1 2026 at Astrazeneca, up from -$25.3 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $22.5 billion in Q4 2024 to a low of -$25.3 billion in Q4 2025.
• Historically, Accounts Payables has averaged -$14.5 billion across 5 years, with a median of -$19.7 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables jumped 777.41% in 2023, then plunged 212.53% in 2025.
• A 5-year view of Accounts Payables shows it stood at $2.6 billion in 2022, then surged by 777.41% to $22.4 billion in 2023, then grew by 0.41% to $22.5 billion in 2024, then slumped by 212.53% to -$25.3 billion in 2025, then grew by 10.98% to -$22.5 billion in 2026.
• The last three Accounts Payables figures came in at -$22.5 billion (Q1 2026), -$25.3 billion (Q4 2025), and -$25.0 billion (Q3 2025), per Business Quant data.